Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03928288 · ClinicalTrials.gov registry record · Phase 2
Cabergoline for the Treatment of Chronic Pain Due to Endometriosis
A Phase 2 study of Endometriosis, sponsored by Boston Children's Hospital.
- Completed
- Registry status
- Phase 2
- Development phase
- 129
- Enrollment target
- 6
- Study locations
NCT03928288 is a Phase 2 study of Endometriosis that has completed, run by Boston Children's Hospital. The registered enrollment target is 129 participants, below the 262-participant average among 48 other Endometriosis trials with a reported enrollment target (51% lower). The trial reports 6 study locations across 4 states.
The verdict
NCT03928288, a Phase 2 study of Endometriosis, has completed, sponsored by Boston Children's Hospital.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 129 participants
- Enrollment target
- 6
- Study locations
Study Summary
Endometriosis is dependent on angiogenesis (the sprouting of new blood vessels) for its growth and maintenance, but the side effects of currently approved angiogenesis inhibitors make these agents inappropriate for use in reproductive-age patients. This obstacle will be overcome by performing a randomized, double blind clinical trial aimed at repurposing an existing drug, cabergoline, as a safe, alternative angiogenesis inhibitor for adolescents and young women with endometriosis. This trial proposes a novel, non-hormonal, non-surgical therapeutic approach aimed at alleviating the pain and suffering associated with this common chronic disease that currently has limited treatment options.
Conditions Studied
Interventions
- DRUG Cabergoline 0.5 MG
- DRUG Placebo - Cap
Study Locations (6)
Massachusetts
- Beth Israel Deaconess Medical Center - Boston
- Brigham and Women's Hospital - Boston
- Children's Hospital Boston - Boston
California
- Standford University - Palo Alto
Colorado
- Childrens Hospital Colorado - Aurora
Pennsylvania
- Thomas Jefferson University Hospital - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 129 participants |
| Start Date | 2019-12-02 |
| Est. Completion | 2026-01-14 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03928288
The ClinicalTrials.gov registry entry for NCT03928288 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 129 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 262-participant average among 48 other Endometriosis trials with a reported enrollment target (51% lower). The listed sponsor is Boston Children's Hospital, which has 462 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Endometriosis appearing as the primary indexed condition, and to 2 interventions - of which Cabergoline 0.5 MG is the first listed.
NCT03928288 reports 6 study locations spanning 4 distinct geographic areas - top geographies include Massachusetts, California, Colorado.
Frequently Asked Questions
What is clinical trial NCT03928288 about?
NCT03928288 is a clinical study titled "Cabergoline for the Treatment of Chronic Pain Due to Endometriosis". Endometriosis is dependent on angiogenesis (the sprouting of new blood vessels) for its growth and maintenance, but the side effects of currently approved angiogenesis inhibitors make these agents inappropriate for use in reproductive-age patients. This obstacle will be overcome by performing a rand...
What is the current status of trial NCT03928288?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 129 participants. The study started on 2019-12-02. Estimated completion is 2026-01-14.
What conditions does trial NCT03928288 study?
This clinical trial studies the following conditions: Endometriosis.
What interventions are being tested in trial NCT03928288?
The interventions under investigation include: Cabergoline 0.5 MG (DRUG), Placebo - Cap (DRUG).
Who is sponsoring clinical trial NCT03928288?
This trial is sponsored by Boston Children's Hospital, which has 462 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03928288 being conducted?
This trial has 6 study locations across California, Colorado, Massachusetts, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Endometriosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Evaluation of Endometriosis With 18F-fluorofuranylnorprogesterone PET / MRI
RECRUITING · Phase 2
-
Evaluating the Impact of a Novel Cannabinoid Product for Endometriosis
RECRUITING · Phase 2
-
Proof of Concept Study to Eval MetriDx Lab-developed Test to Identify Endometriosis-specific Bio Markers
RECRUITING · Phase 2
-
Glycemic Regulation as Endometriosis Adjunct Treatment
RECRUITING · Phase 2
-
The Effect of Hormonal Add-Back Therapy in Adolescents Treated With a GnRH Agonist for Endometriosis: A Randomized Trial
COMPLETED · Phase 2
-
Endometriosis Trial: Study of NBI-56418 in Endometriosis
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.